Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COCH
COCH logo

COCH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.800
Open
0.800
VWAP
0.72
Vol
237.86K
Mkt Cap
58.43M
Low
0.640
Amount
170.36K
EV/EBITDA(TTM)
--
Total Shares
76.88M
EV
33.18M
EV/OCF(TTM)
--
P/S(TTM)
114.20
Envoy Medical, Inc. is a hearing health company. The Company is engaged in providing medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they require. Its hearing solutions include hearing aids, middle ear implants, bone conduction devices and cochlear implants. The bone conduction hearing device has two components: an external component and a surgically implanted fixture placed in the bone behind the ear. Its bone conduction hearing device offers amplification without ear mold in the ear. Its hearing aids are devices that amplify sound for those with mild to moderate hearing loss. Its Esteem is a fully implanted active middle ear implant designed to improve the hearing of adults diagnosed with moderate to severe sensorineural hearing loss. Cochlear implants are a solution for people with moderate-to-profound sensorineural hearing loss.
Show More

Events Timeline

(ET)
2026-06-02
08:50:00
Envoy Medical Signs Media Deal with New to The Street
select
2025-12-18 (ET)
2025-12-18
17:30:00
Envoy Medical Files to Sell Class A Common Stock
select
2024-11-14 (ET)
2024-11-14
07:42:28
Envoy Medical reports Q3 EPS (37c) vs. 13c last year.
select
2024-11-01 (ET)
2024-11-01
08:05:27
Envoy Medical receives FDA approval to initiate study for hearing device
select
2024-10-24 (ET)
2024-10-24
08:27:06
Envoy Medical supports ITEM Coalition letter to CMS on hearing devices
select
2024-10-22 (ET)
2024-10-22
08:22:48
Envoy Medical announces AMA CPT Editorial Panel approved codes for AMEI
select
2024-10-01 (ET)
2024-10-01
08:17:55
Envoy Medical celebrates one year trading as public company
select
2024-09-23 (ET)
2024-09-23
08:04:21
Envoy Medical investor discusses Apple AirPods Pro 2 hearing aid announcement
select

News

Globenewswire
1.0
06-26Globenewswire
Virtual Investor Conferences Forum Highlights
  • On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
  • Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
  • Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
  • Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
seekingalpha
8.5
06-25seekingalpha
Envoy Medical Terminates ATM Equity Facility, Impacting Future Capital Raising
  • Termination of Financing Channel: Envoy Medical announced the termination of its ATM equity facility effective June 24, 2026, which previously allowed the company to issue and sell up to $15 million in common stock over time, providing flexibility for future capital raising.
  • Reduced Dilution Risk: The termination means the company will lose this potential equity issuance channel, which may reduce future shareholder dilution risk; however, it also limits its financing capabilities, potentially impacting the company's expansion plans.
  • Market Reaction Anticipation: The market may react negatively to this news, and investors should monitor how the company adjusts its financing strategy in response to this change, especially as capital demands rise.
  • Strategic Adjustment Necessity: Envoy Medical needs to reassess its capital structure and financing strategies to ensure effective support for future business growth and R&D investments, particularly in the highly competitive medical device market.
Globenewswire
1.0
06-23Globenewswire
Agenda Announced for Life Sciences Virtual Investor Forum
  • Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
  • Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
  • Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
  • Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
seekingalpha
9.5
03-23seekingalpha
Envoy Medical Reports FY 2025 Financial Results
  • Financial Overview: Envoy Medical's FY 2025 GAAP EPS stands at -$1.23 with revenue of only $0.02M, indicating significant challenges in revenue growth that may impact investor confidence.
  • Sales and Marketing Expenses: As of December 31, 2025, sales and marketing expenses were $1,220, down $514 from $1,734 in 2024, primarily due to reduced legal fees associated with the Esteem FI-AMEI product, reflecting the company's efforts in cost control.
  • Rising Administrative Costs: General and administrative expenses increased to $7,931 in FY 2025 from $6,826 in 2024, up $1,105 mainly due to severance costs for the former CFO and increased consulting expenses, indicating financial pressure amid management changes.
  • Cash Position: As of December 31, 2025, Envoy Medical had approximately $3.7 million in cash, which, while adequate, may limit operational flexibility given the ongoing losses.
seekingalpha
8.5
02-24seekingalpha
Envoy Medical Regains Nasdaq Compliance
  • Compliance Notification: Envoy Medical announced it has received a notice from Nasdaq confirming its regained compliance under Rule 5550(b) through permitted alternatives, indicating an improvement in the company's market value compliance.
  • Market Value Issue: The company previously received a Nasdaq notice on February 25, 2025, for failing to meet the minimum $35 million market value requirement for listed securities, highlighting challenges in maintaining its market position.
  • Confidence in Compliance Plan: Envoy Medical stated it believes it has developed an achievable plan to maintain compliance, which is expected to bolster investor confidence in the company's future prospects.
  • Funding Initiative: The company also announced a public offering of up to $78 million, which is anticipated to further strengthen its capital base and support future business expansion.
seekingalpha
8.5
02-11seekingalpha
Envoy Medical Prices Upsized Public Offering of 75M Shares
  • Offering Size: Envoy Medical announced an upsized public offering of 75 million shares of Class A common stock, along with Series A-1 and A-2 common warrants, priced at $0.40 per share, which is expected to generate approximately $30 million in gross proceeds, enhancing liquidity for future growth initiatives.
  • Warrant Details: The Series A-1 warrants have an exercise price of $0.40 per share and will become exercisable upon stockholder approval, expiring 24 months later, while the Series A-2 warrants, also priced at $0.40, will be exercisable for 60 months, reflecting the company's confidence in future FDA approvals.
  • Use of Proceeds: Envoy Medical intends to utilize the net proceeds from the offering for working capital and other general corporate purposes, particularly to fund its FDA pivotal clinical study, thereby advancing the commercialization of its Acclaim cochlear implant.
  • Market Reaction: Despite a 2.51% decline in COCH's stock price to $0.3801 following the offering announcement, the potential additional gross proceeds from the warrants could reach $48 million, indicating the company's strategic positioning and fundraising capabilities for future developments.

Valuation Metrics

The current forward P/E ratio for Envoy Medical Inc (COCH.O) is 0.00, compared to its 5-year average forward P/E of -1.83. For a more detailed relative valuation and DCF analysis to assess Envoy Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.83
Current PE
0.00
Overvalued PE
-0.18
Undervalued PE
-3.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.73
Undervalued EV/EBITDA
-3.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
107.03
Current PS
0.00
Overvalued PS
198.65
Undervalued PS
15.41

Financials

AI Analysis
Annual
Quarterly

Whales Holding COCH

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Envoy Medical Inc (COCH) stock price today?

The current price of COCH is 0.7087 USD — it has decreased -6.71

What is Envoy Medical Inc (COCH)'s business?

Envoy Medical, Inc. is a hearing health company. The Company is engaged in providing medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they require. Its hearing solutions include hearing aids, middle ear implants, bone conduction devices and cochlear implants. The bone conduction hearing device has two components: an external component and a surgically implanted fixture placed in the bone behind the ear. Its bone conduction hearing device offers amplification without ear mold in the ear. Its hearing aids are devices that amplify sound for those with mild to moderate hearing loss. Its Esteem is a fully implanted active middle ear implant designed to improve the hearing of adults diagnosed with moderate to severe sensorineural hearing loss. Cochlear implants are a solution for people with moderate-to-profound sensorineural hearing loss.

What is the price predicton of COCH Stock?

Wall Street analysts forecast COCH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Envoy Medical Inc (COCH)'s revenue for the last quarter?

Envoy Medical Inc revenue for the last quarter amounts to 39.00K USD, decreased -15.22

What is Envoy Medical Inc (COCH)'s earnings per share (EPS) for the last quarter?

Envoy Medical Inc. EPS for the last quarter amounts to -0.08 USD, decreased -72.41

How many employees does Envoy Medical Inc (COCH). have?

Envoy Medical Inc (COCH) has 43 emplpoyees as of July 09 2026.

What is Envoy Medical Inc (COCH) market cap?

Today COCH has the market capitalization of 58.43M USD.